New stroke drug TAK-755 enters human trials – could improve recovery
NCT ID NCT07392450
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether TAK-755, a lab-made protein that helps break up blood clots, is safe and effective for people who have had an acute ischemic stroke. About 222 adults aged 18 to 80 will receive either TAK-755 or a placebo, along with standard stroke care, and be monitored for 90 days. The main goal is to check for bleeding in the brain, while also seeing if the drug helps reduce stroke severity and improve daily functioning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-755 (a lab-made version of a natural protein that helps break up blood clots)
What this could lead to
If it works, this could lead to a new treatment that helps people recover better after a stroke and reduces long-term disability.
What could go wrong
This is an early phase 2 trial with only 222 people, so results may not apply to everyone. There is also a risk of bleeding in the brain, which the study is carefully monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health
RECRUITINGScottsdale, Arizona, 85251, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••